Immutep (IMMP) said Thursday its investigational drug eftilagimod alpha, or efti, combined with Merck's (MRK) Keytruda and doublet chemotherapy achieved a response rate of 60.8% and disease control rate of 90.2% in patients with advanced or metastatic non-squamous non-small cell lung cancer in an investigator-initiated trial.
The company said the 60.8% response rate regardless of PD-L1 expression is a "substantial improvement" from the historical control of 48%.
Safety continues to be favorable for the triple combination, the company said.
Immutep said it expects to present additional data from the trial at a medical conference within the year.
Shares of Immutep climbed 9.3% in recent premarket activity Thursday, while Merck shares added 1%.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。